Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03930173 · ClinicalTrials.gov registry record · Early Phase 1
18F-Fluciclovine PET to Distinguish Tumor Progression From Radiation Necrosis
A Early Phase 1 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 18
- Enrollment target
NCT03930173 is a Early Phase 1 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 18 participants.
The verdict
NCT03930173, a Early Phase 1 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether 18F-fluciclovine PET/CT of the brain, is able to distinguish radiation necrosis from tumor progression in cases where MRI is inconclusive. 18F-fluciclovine is an FDA approved radioactive diagnostic agent and is injected into the participant and then taken up by cancer cells, which can then be visualized with a PET/CT scan. 18F-fluciclovine is FDA approved for the detection of recurrent prostate cancer, but is still investigational for the purposes of this study.
Interventions
- DRUG 18F-fluciclovine
- DEVICE PET/CT of the brain
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-07-02 |
| Est. Completion | 2021-03-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03930173
The ClinicalTrials.gov registry entry for NCT03930173 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 18F-fluciclovine is the first listed.
NCT03930173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03930173 about?
NCT03930173 is a clinical study titled "18F-Fluciclovine PET to Distinguish Tumor Progression From Radiation Necrosis". The purpose of this study is to evaluate whether 18F-fluciclovine PET/CT of the brain, is able to distinguish radiation necrosis from tumor progression in cases where MRI is inconclusive. 18F-fluciclovine is an FDA approved radioactive diagnostic agent and is injected into the participant and then ...
What is the current status of trial NCT03930173?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 18 participants. The study started on 2019-07-02. Estimated completion is 2021-03-01.
What interventions are being tested in trial NCT03930173?
The interventions under investigation include: 18F-fluciclovine (DRUG), PET/CT of the brain (DEVICE).
Who is sponsoring clinical trial NCT03930173?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.